TriaGen Wealth Management LLC Purchases Shares of 13,036 Danaher Co. (NYSE:DHR)

TriaGen Wealth Management LLC purchased a new stake in Danaher Co. (NYSE:DHR) during the third quarter, Holdings Channel reports. The firm purchased 13,036 shares of the conglomerate’s stock, valued at approximately $3,624,000. Danaher comprises 1.2% of TriaGen Wealth Management LLC’s portfolio, making the stock its 14th biggest holding.

Other large investors have also recently bought and sold shares of the company. Benjamin Edwards Inc. boosted its holdings in Danaher by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after acquiring an additional 38 shares during the last quarter. Wedge Capital Management L L P NC boosted its holdings in Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 38 shares during the last quarter. Patrick M Sweeney & Associates Inc. boosted its holdings in Danaher by 3.4% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after acquiring an additional 40 shares during the last quarter. Trust Co of Kansas boosted its holdings in Danaher by 4.1% in the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after acquiring an additional 40 shares during the last quarter. Finally, Abacus Planning Group Inc. boosted its holdings in Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after acquiring an additional 40 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Up 0.9 %

Shares of NYSE DHR traded up $2.40 during mid-day trading on Friday, reaching $274.38. 1,949,849 shares of the company’s stock were exchanged, compared to its average volume of 2,717,951. The firm has a market capitalization of $203.23 billion, a price-to-earnings ratio of 46.50, a PEG ratio of 4.49 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The business has a fifty day simple moving average of $270.72 and a 200 day simple moving average of $259.92. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period last year, the company earned $2.05 earnings per share. As a group, equities analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s payout ratio is presently 18.31%.

Insider Buying and Selling

In related news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on DHR shares. Stephens started coverage on Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price target on the stock. Barclays increased their target price on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group increased their target price on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Leerink Partners increased their target price on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, Robert W. Baird increased their target price on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $282.12.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.